Skip to main content

Ryght AI

Category: AI in Healthcare

An enterprise-grade generative AI platform and orchestration layer designed specifically for life sciences to accelerate clinical trials and optimize biopharma workflows. Ryght AI was founded in 2023. The company is led by Simon Arkell. Based in Laguna Beach, United States. Team size: 22. Total funding raised: ~$13M total (all rounds). Latest round: Series A ($8M, Sep 2024 led by Reemy Ventures && Quest Venture Partners). Key investors include Foothill Ventures, AIX Ventures, Accenture Ventures, Virtue Ventures, Capital One Ventures, IASO Ventures, Top Harvest Capital, Page One Ventures.

Founded
2023
Headquarters
Laguna Beach, United States
Team size
22
Total funding
~$13M total (all rounds)

Value proposition

Ryght accelerates clinical trials by automating documentation, site selection, and data analysis using secure, hallucination-free generative AI agents ('Agentic AI') and Digital Site Twins.

Products and solutions

Ryght GenAI Platform, Ryght Knowledge (Protocol analysis), Ryght Build (AI agent creation), Ryght Run (Inference), AI Site Twins (Digital replicas of research sites)

Unique value

Combines a secure, enterprise-grade orchestration layer with 'Agentic AI' capable of complex autonomous tasks (like site feasibility analysis) and 'AI Site Twins' to digitize trial locations globally.

Target customer

Biopharmaceutical companies, CROs (Contract Research Organizations), and Academic Medical Centers

Industries served

Life Sciences, Pharmaceuticals, Clinical Research

Technology advantage

Proprietary tuning of LLMs for biomedical context, reducing hallucinations common in general-purpose models. The 'Site Twin' technology creates dynamic digital replicas of clinical sites to predict enrollment performance.

How they differentiate

Ryght focuses specifically on the 'GenAI Orchestration' layer and autonomous agents for site operations, whereas competitors often focus on static data sets or patient-matching specifically. Ryght positions itself as a 'Service-as-Software' for operations.

Main competitors

IQVIA, Castor, Unlearn.AI, Altis Labs, Deep 6 AI (now part of Tempus), Lokavant, H1

Key partnerships

Accenture (Strategic Investment & Go-to-Market), NVIDIA (Inception Program), Microsoft (Azure Marketplace), QPS Holdings, Cancer Research South Australia, Various Academic Medical Centers

Notable customers

Emory University, West Virginia University, USC Keck School of Medicine, QPS Holdings, Cancer Research South Australia

Major milestones

Founded in 2023 as Synthetica Bio, Rebranded to Ryght AI (November 2023), Launched GenAI Platform for Life Sciences (2024), Raised $3M Seed Round led by Foothill Ventures (June 2025), Secured Strategic Investment from Accenture (December 2025), Partnership with QPS Holdings (January 2025)

Growth metrics

Partnerships with 8+ leading Academic Medical Centers; Strategic investment from Accenture; Over 100,000 research sites in global network

Market positioning

Emerging leader in GenAI-first clinical operations software

Geographic focus

North America (United States) with global reach via CRO partners

Patents and IP

N/A (Software/Algorithm IP likely protected as trade secrets or provisional)

About Simon Arkell

Serial entrepreneur and two-time Olympian (pole vault). Co-founder of seven venture-backed companies including Deep Lens (acquired by Paradigm Health), Predixion Software (acquired by Greenwave Systems), and Versifi. Over 20 years of experience in AI, healthcare technology, and data analytics.

Official website: